Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017

Daiichi Sankyo press release ---- Daiichi Sankyo Company, Limited, today announced the following organizational changes taking place from April 1,2017. Corporate --- In order to accelerate the advancement of the Daiichi Sankyo Cancer Enterprise and strengthen our product portfolio management, “Global Brand Strategy Division,” will be newly established with the “Global Specialty & Value Products Marketing” and “Intellectual Property” departments falling under it. R&D Division---- In order to strengthen our translational function between drug research and development, and to accelerate the development of personalized medicines, related functions will be gathered in the newly established, “Biomarker Department,” which falls under the Oncology Function. Biologics Division ---- “Biologics Division” will be newly established with the integration of biologics-related functions, including modality research, industrial science research, investigational product manufacturing, and commercial production functions. To learn more about Daiichi Sankyo organizational restructuring click on the picture below to read the release.